Levenza still wins risk-adjusted, but Stilta enters at #2 with the truest founding-GTM seat
Asked (summary):
Which opportunity is best to join as a founding AE: 1) Levenza — $0 to $6M this year, $30M projected next year, bootstrapped, 8 employees, just hired a Head of Strategic Accounts, hiring its first AE; 2) Kos — $1M closed, $20M pipeline of which $8M is one account, hiring its first 2 AEs, no sales leader; or 3) Petra Security — 5th AE, about to hit $10M ARR, projecting $40M next year?
Asked (follow-up):
“how about all of those opps vs. founding AE at stilta.com?”
This update compares all four seats as of 30 October 2026. The four-row comparison spans four source hosts (no URL supports more than one row), plus nine official Stilta pages, 24 postings of Stilta's founding GTM role, and 50 third-party articles on its funding, customers, and competitors. The user's revenue figures for Levenza, Kos, and Petra are unverified; Stilta traction is mostly company-reported.
Updated ranking: Stilta enters at #2
Left: prior ranking (three seats). Right: updated ranking with Stilta added. Blue marks the new entrant; grey lines show seats that moved down one slot. Ranks are risk-adjusted judgments, not scores.
Scorecard: nine criteria, four seats
Qualitative levels from the postings and public materials: dark = strong or favourable, light = weak, hatched grey = unknown. Hover or tap a cell for the evidence behind it.
Findings
Stilta's role is the only one with a published range on both pay and ownership: $100K–$200K and 0.40%–0.80% equity, owning prospecting through close, playbook, demos, CRM and forecasting —
ycombinator.comStilta raised a $10.5M seed led by Andreessen Horowitz with YC participating, and says Roche, Alfa Laval and Maersk plus three of the five largest IP firms are signed as customers or active pilots — "signed" mixes the two —
stilta.comProduct proof is real but company-published: a Maersk benchmark reported 88% agreement on 143 of 163 patent-to-product mappings (97% where public evidence was complete), and the comparable set excluded products without public evidence —
stilta.comA KUKA re-run reached the same no-infringement conclusion autonomously in about 20 minutes, 85–90% less time than the manual assessment —
stilta.comWhy not automatically #1: no public ARR, ACV, pilot-to-paid or cycle data; every deal founder-closed; the buyer is a sceptical senior patent attorney; incumbents and funded rivals (Clarivate, Thomson Reuters, Patlytics, Solve Intelligence) crowd the space —
legaltechmonitor.com
The four seats, side by side
| Company | Role | Compensation | Call | Source |
|---|
Levenza, Kos and Petra revenue figures in the ranking come from the user and are unverified; Levenza's and Stilta's traction claims are company-published.
Decision rule
Choose Stilta over Levenza if diligence shows at least 5–8 paid customers (not mostly pilots), multiple non-founder-led deals advanced or closed, a quota grounded in real ACV and cycle length, and the 0.40%–0.80% as a fully diluted grant with reasonable strike and exercise terms.
Choose
Levenza if its equity is meaningful and the account split beneath the new Head of Strategic Accounts — publicly described as the founding commercial leader with a CRO/COO path — still leaves true ownership (
localwork.com).
Choose
Petra for cash and lower sales risk: $200K–$300K OTE against mid-seven-figure ARR and $30K–$150K ACVs (
lensa.com).
Choose
Kos only after CRM-level diligence shows the pipeline outside the $8M account is diversified and late-stage (
kos.ai).
Stilta diligence list — before accepting
- Exact paid ARR and bookings; count of paid customers vs active pilots
- Customer concentration; ACV by law firm vs enterprise; contract length
- Pilot-to-paid conversion rate and sales cycle length
- Who sourced each deal to date; renewals and expansions so far
- Proof a non-founder can run demos and close with senior patent attorneys
- Implementation hours per customer; security and professional-liability objections
- Sales quota, ramp, and whether $100K–$200K is base or OTE
- Equity on a fully diluted basis: preferred valuation, strike price, expected dilution, vesting, acceleration, exercise window
- New York vs Stockholm territory split and founder coverage
- Whether the title is Founding GTM, Founding AE, or future sales leader
- What triggers hiring AE #2 or a VP Sales
Method: four-seat comparison assembled 30 Oct 2026 from one clean four-row result set (one source host per company), nine official Stilta pages, 24 Stilta sales-role postings (the YC listing is primary), and 50 third-party articles. Scorecard cells are qualitative levels (strong / moderate / weak / unknown) judged from those sources, not measurements. User-supplied revenue figures for Levenza, Kos, and Petra are unverified; Stilta benchmarks are company-published. Full posting texts and most third-party articles were cut for space.